

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

j1017 U.S. PTO
10/077894
02/20/02

In re PATENT APPLICATION of

Bartlett et al.

Group Art Unit: 1632

Appln. No.: (To be assigned)

Examiner:

Filed: February 20, 2002

Title: USE OF CHIMERIC MUTATIONAL VECTORS TO CHANGE
ENDOGENOUS NUCLEOTIDE SEQUENCES IN SOLID TISSUES

* * * * *

February 20, 2002

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Sir:


Attached is Form PTO-1449 listing referenced relied upon by the Applicants and cited by the USPTO during examination of the parent application U.S. Serial No. 09/576,081, filed May 20, 2000. Pursuant to Rule 98(d), copies of those documents are not required. Applicants respectfully request that those documents be considered in this application and that Applicant be advised of same by returning a copy of the attached Form PTO-1449 with the Examiner's initials in the left column per MPEP 609.

This Information Disclosure Statement is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been

omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to comply fully.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By _____
Robin L. Teskin, Esq.
Registration No. 35.030

1600 Tysons Boulevard
McLean, VA 22102
(703) 905-2000
(703) 905-2500 Fax

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

Atty.
Dkt. No.

M#

Client Ref.

0280699

7991-050-999 Cont

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: BARTLETT et al.

Appln. No.: (TBA)

Filing Date: February 20, 2002

Date: February 20, 2002

Page

1

of

2

Examiner: Unknown

Group Art Unit: 1632

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR 5,565,350	10/1996	KMIEC			
	BR 5,731,181	03/1998	KMIEC			
	CR 5,849,482	12/1998	MEYER, JR. et al.			
	DR 5,888,983	03/1999	KMIEC et al.			
	ER 6,004,804	12/1999	KUMAR et al.			
	FR 6,010,907	01/2000	KMIEC et al.			
	GR 6,136,601	10/2000	MEYER, JR. et al.			

FOREIGN PATENT DOCUMENTS

Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
				Enclosed	No
HR WO 99/40789	08/1999	WIPO	STEER et al.		

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

IR	ALEXEEV et al., "Stable and inheritable changes in genotype and phenotype of albino melanocytes induced by an RNA-DNA oligonucleotide," NATURE BIOTECHNOLOGY, Volume 16, December 1999, pages 1343-1346				
JR	ALEXEEV et al., "Localized in vivo genotypic and phenotypic correction of the albino mutation in skin by RNA-DNA oligonucleotide," NATURE BIOTECHNOLOGY, Volume 18, January 2000, pages 43-47				
KR	BARTLETT et al., "In vivo targeted repair of a point mutation in the canine dystrophin gene by a chimeric RNA/DNA oligonucleotide," NATURE BIOTECHNOLOGY, Volume 18, June 2000, pages 615-622				
LR	SMAGLIK, "Chimeraplasty Potential," The Scientist 14[1]:13, Jan. 10, 2000 (Internet version)				
MR	Bartlett et al., "Targeted Reversion of the <i>mdx</i> Point Mutation," Nature Biotechnology Short Report, 9, 1998, pp. 163-164				
NR	Pegoraro et al; "Genetic and Biochemical Normalization in Female Carriers of Duchenne Muscular Dystrophy ... myonuclei, 1995, Neurology 45:6777-690				
OR	Stephenson; New Method to Repair Faulty genes Stirs Interest in Chimeraplasty Technique, 1999, JAMA, Vo. 281, No. 2:199-121				
PR	Van der Steege et al.; Persistent Failures in Gene Repair, 2001, Nature Biotechnology Vol. 19:305-306.				

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

Atty.
Dkt. No.

M#

Client Ref.

0280699

7991-050-999 Cont

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: BARTLETT et al.

Appln. No.: (TBA)

Filing Date: February 20, 2002

Date: February 20, 2002

Page

1

of

2

Examiner: Unknown

Group Art Unit: 1632

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	QR					

FOREIGN PATENT DOCUMENTS

Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
				Enclosed	No
	RR				

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

SR	Kren et al., "Targeted Nucleotide Exchange in the Alkaline Phosphatase Gene of HuH-7 Cells Mediated by a Chimeric RNA/DNA Oligonucleotide," Hepatology Vol. 25, No. 6, 1997, pp. 1462-1468				
TR	Strauss, "The site-specific correction of genetic defects," Nature Medicine, Volume 4, March 1998, pp. 274-275				
UR	Kren et al., "In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides," Nature Medicine, Volume 4, March 1998, pp. 285-290				
VR	Bandyopadhyay et al., "Nucleotide Exchange in Genomic DNA of Rat Hepatocytes Using RNA/DNA Oligonucleotides," The Journal Of Biological Chemistry, Vol. 274, Issue of April 9, 1999, pp. 10163-10172				
WR	Kren et al., "Correction of the UDP-glucuronosyltransferase gene defect in the Gunn rat model of Crigler-Najjar syndrome type I with a chimeric oligonucleotide," Proc. Natl. Acad. Sci., Vol. 96, August 1999, pp. 10349-10354				
XR	Culver et al., "Correction of chromosomal point mutations in human cells with bifunctional oligonucleotides," Nature Biotechnology, Vol. 17, October 1999, pp. 989-993				
YR	Yoon, Single-base Conversion of Mammalian Genes by an RNA-DNA Oligonucleotide, 1999, Biogenic Amines, Vol. 15, no. 1:137167				
ZR					

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.